Advancing new potential treatments for certain GI diseases affecting millions of patients in need

  • Product
  • Indication
  • PHASE I
  • PHASE II
  • PHASE III
  • Approval
  • Linzess® Partner
  • Launched 12/12

  • linaclotide Partner
  • Functional constipation pediatrics

  • IW-3718
  • Persistent GERD

  • Phase III trial results targeted 2H 2020
  • MD-7246 Partner
  • Abdominal pain associated with IBS with diarrhea (IBS-D)

  • Phase II trial results targeted mid-2020

Represents current phase of development, does not correspond to the initiation or completion of a particular phase.

Status of key development programs as of October 31, 2019.

Click here for LINZESS® full US Prescribing Information including BOXED WARNING.

Copyright © 2020, Ironwood Pharmaceuticals, Inc. All Rights Reserved

LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.